Loading...

AKRO AKERO THERAPEUTICS INC Product Launches 8-K Filing

KR T

KR

AKERO THERAPEUTICS INC

(AKRO)

2023 8-K

Show Summary

Show Summary

Financial Statements

Financial Results

Clinical Study Results

Financial Results

Financial Results Announcement

Annual Meeting of Stockholders

Financial Results Announcement

Warrant Issuance

Underwriting Agreement

HARMONY Study Results

Financial Results Announcement

Phase 3 Clinical Study Anno...

Financial Results Announcement

Financial Results Announcement

Annual Meeting of Stockholders

Financial Update

Underwriting Agreement

Financial Results Announcement

FDA Meeting and Phase 3 Pro...

Open Market Sale Agreement

Financial Results Announcement

External Links:

Akero Therapeutics announced the dosing of the first patients in its Phase 3 clinical study of efruxifermin for the treatment of non-alcoholic fatty liver disease.

AI Assistant

AKERO THERAPEUTICS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.